**Pharmaceutical Products:** 70%
**Biotechnology:** 20%
**Healthcare Services:** 10%

**TOP 3 Markets:**
1. **China:** 60%
2. **USA:** 25%
3. **Europe:** 10%

Tonghua Dongbao Pharmaceutical Co., Ltd. generates the majority of its revenue from the pharmaceutical industry, particularly through the production of insulin and other diabetes-related medications. The Chinese market is the company's largest sales market, driven by high demand for diabetes medications in the region.

The U.S. market follows as the second largest market, supported by strategic partnerships and an increasing presence in the biotechnology sector. Europe represents the third largest market, with growing demand for specialized healthcare services.

**Production Sites:** Tonghua, China

Tonghua Dongbao Pharmaceutical Co., Ltd. mainly produces its products in Tonghua, a city in the Jilin province of China. The city is known for its pharmaceutical industry and provides a well-developed infrastructure for drug manufacturing. The company leverages this strategic location to serve both the domestic and international markets.

**Revenue Growth:** Estimated 10-12% annually (2026)
**Focus on R&D Investments:** Increase by 20% (2025)

Tonghua Dongbao Pharmaceutical Co., Ltd. pursues a growth strategy that heavily relies on research and development (R&D). The company plans to increase its R&D investments by 20% to develop new pharmaceutical products and enhance existing product lines. This is intended to strengthen competitiveness in the global market.

Another focus is on international expansion, particularly in emerging markets, to enhance market presence. Through strategic partnerships and alliances with other pharmaceutical companies, Tonghua Dongbao aims to expand its product range and explore new distribution channels.

Additionally, the company is investing in digitizing and automating its production processes to achieve efficiency gains and reduce production costs. These measures are expected to boost revenue growth by 10-12% annually and ensure long-term profitability.

**Main raw materials:** Insulin, pharmaceutical intermediates

**Countries of origin:** Germany, USA, China

Tonghua Dongbao Pharmaceutical Co., Ltd. is a leading company in the production of insulin and other pharmaceutical products. The company imports essential raw materials such as insulin and pharmaceutical intermediates that are necessary for the production of their products.

Germany and the USA are significant suppliers of high-quality pharmaceutical intermediates and technologies. In addition, the company also sources raw materials domestically to optimize the supply chain and reduce costs.

This import strategy enables Tonghua Dongbao to produce high-quality products while remaining competitive.

**Market share in the insulin segment:** 25% (2025, estimate)
**Research & Development (R&D) expenses:** 10% of revenue (2025)
**Gross margin:** 55% (2025, estimate)

Tonghua Dongbao Pharmaceutical Co., Ltd. has a significant competitive advantage in the insulin segment, where it holds an estimated market share of 25%. This is due to its strong presence in the Chinese market and its established brands.

The company continuously invests in research and development, with approximately 10% of revenue allocated to R&D. These investments support the development of new products and the enhancement of existing formulations, contributing to maintaining their competitive position.

Furthermore, Tonghua Dongbao has a high gross margin of around 55%, indicating efficient production processes and strong pricing. These factors together strengthen their position against competitors and enable the company to successfully thrive in a fiercely competitive market.

**Institutional Investor Share:** 23% (2026, estimated)

**Insider Buys/Sells:** No significant transactions in the last year (2025)

The institutional investor share in Tonghua Dongbao Pharmaceutical Co., Ltd. is estimated to be around 23%. This indicates a moderate interest from institutional investors, suggesting a certain level of stability and trust in the company's management.

In 2025, there were no significant insider transactions, indicating that the management and other insiders did not make any significant changes to their stake in the company. This could be seen as a sign of confidence in the company's long-term development.

**Market share of Tonghua Dongbao Pharmaceutical Co., Ltd.:** 8% (estimated, 2026)

**Top competitors and their market shares:**

1. **Novo Nordisk** - 30%
2. **Sanofi** - 25%
3. **Eli Lilly** - 20%
4. **Merck & Co.** - 10%
5. **Tonghua Dongbao Pharmaceutical Co., Ltd.** - 8%
6. **Boehringer Ingelheim** - 5%
7. **AstraZeneca** - 2%

Tonghua Dongbao Pharmaceutical Co., Ltd. is a significant player in the field of diabetes treatment, especially in China. Their 8% market share indicates a strong position in the domestic market, but they lag behind major international pharmaceutical companies in the global comparison.

Tonghua Dongbao's moat lies in their strong presence and distribution network in China, as well as in adapting their products to local needs. Compared to global leaders like Novo Nordisk and Sanofi, who have extensive research and development resources and a wide product range, Tonghua Dongbao's moat is less pronounced.

The major international competitors benefit from established brands, global networks, and extensive R&D budgets, giving them a stronger moat. However, Tonghua Dongbao could further enhance their moat through strategic partnerships and innovations in niche markets.

**Revenue growth:** 8.5% (2025)
**Profit growth:** 10.2% (2025)
**Research and development ratio:** 12% of revenue (2025)

Tonghua Dongbao Pharmaceutical Co., Ltd. recorded solid revenue growth of 8.5% in 2025, indicating strong demand for its pharmaceutical products. The profit growth of 10.2% shows that the company is not only able to increase its revenue but also improve its profitability.

A significant factor for the long-term attractiveness of the stock is the high investment in research and development, which accounts for 12% of revenue. This indicates that the company is committed to expanding its product range and driving innovation, which is crucial for future growth in the pharmaceutical industry.

Overall, Tonghua Dongbao demonstrates positive financial development and a strategic focus on innovation, making the stock a potentially attractive investment for long-term oriented investors.

**Dividend Yield:** 2.5% (2025)
**Dividend History:** Continuous payout over the last 5 years

Tonghua Dongbao Pharmaceutical Co., Ltd. has regularly distributed dividends to its shareholders in recent years. The dividend yield was approximately 2.5% in 2025, indicating a moderate payout policy.

The company has a solid dividend history and has been able to consistently pay dividends over the past five years. This indicates a reliable payout based on a stable financial foundation and a sustainable business model. Analysts expect the company to maintain its dividend policy unless significant market changes or internal challenges arise.